Zebularine showed anti-tumor efficacy in clear cell renal cell carcinoma.

ABSTRACT:

Background

Clear cell renal cell carcinoma (ccRCC) has the highest morbidity among renal cell carcinoma (RCC) subtypes. While existing clinical pharmacological intervention strategies have achieved certain efficacy, challenges including inevitable drug resistance and intricate immune heterogeneity of ccRCC continue to hinder their biomedical application. Therefore, developing novel immunotherapeutic agents and identifying patients who can gain the greatest benefits from these therapies are urgent issues.

Methods

To address these challenges, mRNA expression profile and clinical data of ccRCC were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. These data were integrated and randomly allocated into training and test sets. Immune-relate

SUBMITTER: Xu H 

PROVIDER: S-EPMC11868290 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature